Jefferies Financial Group Inc. Trims Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Jefferies Financial Group Inc. decreased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 47.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,304 shares of the specialty pharmaceutical company’s stock after selling 40,875 shares during the period. Jefferies Financial Group Inc. owned 0.08% of Supernus Pharmaceuticals worth $2,252,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of SUPN. Royal Bank of Canada increased its stake in shares of Supernus Pharmaceuticals by 68.1% in the first quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after purchasing an additional 4,729 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Supernus Pharmaceuticals by 35.2% in the first quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock worth $2,791,000 after purchasing an additional 22,182 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Supernus Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock worth $978,000 after purchasing an additional 1,297 shares in the last quarter. Millennium Management LLC increased its stake in shares of Supernus Pharmaceuticals by 370.5% in the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock worth $4,695,000 after purchasing an additional 112,886 shares in the last quarter. Finally, Empowered Funds LLC increased its stake in shares of Supernus Pharmaceuticals by 16.0% in the first quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock worth $1,573,000 after purchasing an additional 6,619 shares in the last quarter.

Insider Activity

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 35,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the completion of the sale, the chief executive officer directly owned 958,100 shares in the company, valued at $48,259,497. The trade was a 3.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Georges Gemayel sold 10,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $53.71, for a total transaction of $537,100.00. Following the sale, the director owned 28,159 shares of the company’s stock, valued at approximately $1,512,419.89. The trade was a 26.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 116,406 shares of company stock valued at $5,911,086 over the last ninety days. 8.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on SUPN shares. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Finally, Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Trading Down 0.9%

SUPN stock opened at $47.77 on Wednesday. The firm has a 50 day moving average of $49.91 and a 200-day moving average of $49.58. Supernus Pharmaceuticals, Inc. has a 12 month low of $30.83 and a 12 month high of $59.68. The firm has a market capitalization of $2.77 billion, a P/E ratio of -93.67, a price-to-earnings-growth ratio of 1.04 and a beta of 0.57.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.